Kura Oncology, Inc. (KURA)
- Previous Close
20.61 - Open
20.92 - Bid 20.86 x 400
- Ask 20.93 x 200
- Day's Range
20.70 - 21.78 - 52 Week Range
7.41 - 24.17 - Volume
461,687 - Avg. Volume
887,226 - Market Cap (intraday)
1.593B - Beta (5Y Monthly) 0.89
- PE Ratio (TTM)
-- - EPS (TTM)
-2.17 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
30.25
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.
kuraoncology.comRecent News: KURA
Performance Overview: KURA
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KURA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KURA
Valuation Measures
Market Cap
1.57B
Enterprise Value
1.06B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.11
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.43%
Return on Equity (ttm)
-37.34%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-168.09M
Diluted EPS (ttm)
-2.17
Balance Sheet and Cash Flow
Total Cash (mrq)
527.12M
Total Debt/Equity (mrq)
3.36%
Levered Free Cash Flow (ttm)
-71.54M
Research Analysis: KURA
Company Insights: KURA
KURA does not have Company Insights